Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 12/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8171335 | 0.90 | ROCK1 (0.46) | ROCK1ROCK2PTK2 | |
| SCHEMBL8174088 | 0.88 | ROCK1 (0.47) | ROCK1ROCK2 | |
| SCHEMBL8166429 | 0.88 | POLB (0.41) | ROCK1MAPTTHRBPOLBLMNA | |
| SCHEMBL8166309 | 0.88 | THRB (0.39) | ROCK1MAPTTHRBPOLBLMNA | |
| SCHEMBL8166227 | 0.87 | ROCK1 (0.44) | ROCK1ROCK2 | |
| SCHEMBL8173430 | 0.87 | ROCK1 (0.39) | ROCK1ROCK2 | |
| SCHEMBL8166436 | 0.85 | ROCK1 (0.45) | ROCK1ROCK2PTK2 | |
| SCHEMBL8172938 | 0.85 | ROCK1 (0.40) | ROCK1ROCK2 | |
| SCHEMBL16938550 | 0.80 | TDO2 (0.35) | MAPTTHRBPOLBLMNAROCK2 | |
| SCHEMBL8166422 | 0.78 | PTK2 (0.35) | MAPTTHRBPOLBLMNAPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | claimed |
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| EP-2155728-B1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | disclosed |
| US-8334309-B2 | Heterocyclic indazole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20110190355-A1 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-04 | — | — | US | disclosed |
| WO-2008138448-A2 | HETEROCYCLIC INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190355-A1 | HETEROCYCLIC INDAZOLE DERIVATIVES | SGK3, SGK2, SGK1 | ROCK1 576/4885MAPT 3913/4885THRB 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.